Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Heterogeneous Tumor Features And Treatment Outcome Between Males And Females With Lung Cancer (LC): Do Gender And Sex Matter?
S. Frega, A. Dal Maso, A. Ferro, L. Bonanno, P. Conte, G. Pasello
Published 2019 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Lung cancer (LC) is the leading cause of cancer-related death worldwide, despite a decreasing incidence rate in recent years, especially in men. Most risk factors for LC could be linked to an individual's reproductive system and secondary sex characteristics ('sex-related') and/or to some physical, behavioral and personality traits ('gender-related') peculiar to males rather than females or vice versa. An imbalance of these etiologic factors could explain why some LC features may differ between sexes. For this review, an extended literature data collection was performed, using keywords to identify 'sex/gender' and 'LC'. Differences between genders in LC epidemiology, pathological and molecular characteristics, loco-regional and/or systemic treatments outcome and prognosis were systematically analyzed. The possible predictive role of physio-pathological factors in males and females paves the way for a personalized therapeutic approach, emphasizing the need to include gender as a stratification factor in future clinical trials design.
This paper references
Associations between Testosterone Levels and Incident Prostate, Lung, and Colorectal Cancer. A Population-Based Study
Zoë Hyde (2012)
Discovery and saturation analysis of cancer genes across 21 tumor types
M. Lawrence (2014)
Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis.
H. Nakamura (2011)
Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer.
C. Yang (2016)
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
A. Aupérin (2010)
First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer
Leora Horn (2018)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
M. Hellmann (2018)
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.
C. Gridelli (2003)
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
W. Travis (2015)
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
J. Pujol (2006)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
M. Frueh (2013)
The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer
K. Chansky (2009)
Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
H. Nelson (1999)
Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
M. Li (2012)
Randomized phase II study of erlotinib (E) alone or combined with fulvestrant (F) in previously treated patients with advanced non-small cell lung cancer (NSCLC).
E. Garon (2010)
Abstract 4664: Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC).
E. Garon (2013)
US lung cancer trends by histologic type
D. Lewis (2014)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
A. Rittmeyer (2017)
Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis.
Y. Zhang (2015)
Dietary factors and risk of lung cancer in never‐smokers
F. Nyberg (1998)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
R. Govindan (2012)
Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer
R. Camidge (2018)
Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women.
J. Girón-González (2000)
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.
C. Delbaldo (2004)
Influence of sex on toxicity and treatment outcome in small-cell lung cancer.
S. Singh (2005)
International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women.
J. Lortet-Tieulent (2014)
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding (2008)
Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis of Randomized Trials
E. Lim (2009)
Body mass index and lung cancer: a case-control study of subjects participating in a mass-screening program.
M. Kanashiki (2005)
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
J. von Pawel (1999)
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
M. Di Maio (2009)
ROS1 expression and translocations in non‐small‐cell lung cancer: clinicopathological analysis of 1478 cases
A. Warth (2014)
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
R. Arriagada (2010)
Estrogen Signaling Contributes to Sex Differences in Macrophage Polarization during Asthma
Aleksander Keselman (2017)
Cytoplasmic expression of estrogen receptor β may predict poor outcome of EGFR-TKI therapy in metastatic lung adenocarcinoma
X. Ding (2018)
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.
C. Mascaux (2000)
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
M. Paesmans (1995)
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
C. Butts (2010)
Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
J. Pinto (2018)
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.
F. Barlesi (2014)
Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599
J. Brahmer (2011)
Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin.
C. Shekhar (2013)
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
É. Quoix (2011)
Participation in cancer clinical trials: race-, sex-, and age-based disparities.
Vivek Murthy (2004)
Role of estrogen receptor in regulation of polycyclic aromatic hydrocarbon metabolic activation in lung.
G. Berge (2004)
Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung.
F. Shepherd (1988)
Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.
G. Lopes (2018)
The Influence of Gender, Race, and Marital Status on Survival in Lung Cancer Patients: Analysis of Radiation Therapy Oncology Group Trials
F. Siddiqui (2010)
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.
C. Rudin (2015)
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells.
M. Ivanova (2010)
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
S. Dogan (2012)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
M. Reck (2014)
Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor.
J. Thomsen (1994)
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
A. Calles (2015)
Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.
J. Mazieres (2018)
Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
R. Gealy (1999)
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer
G. Lin (2017)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
T. Ciuleanu (2009)
P2-106: Gender differences in non-small cell lung cancer (NSCLC) patients (p): A retrospective study based in Spanish Lung Cancer Group(SLCG) trials.
N. Viñolas (2007)
Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
D. Skarlos (2001)
Lung cancer in never smokers: a review.
J. Subramanian (2007)
Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010
R. Meza (2015)
Association of tumor mutational burden with smoking and mutation status in non-small cell lung cancer (NSCLC).
A. Davis (2017)
Cancer statistics, 2019
R. Siegel (2019)
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
J. Morère (2010)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
R. Herbst (2016)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
A. Sharpe (2007)
Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.
H. Wakelee (2012)
Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026
S. Peters (2017)
Lung cancer in women: emerging differences in epidemiology, biology, and therapy.
Leno Thomas (2005)
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.
A. Turrisi (1999)
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
A. Brunelli (2009)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
L. Gandhi (2018)
Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer
Jhajaira M Araujo (2016)
The CYP1A1 gene and cancer susceptibility.
K. Kawajiri (1993)
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.
C. Gridelli (2004)
Topotecan/Cisplatin Compared with Cisplatin/Etoposide as First-Line Treatment for Patients with Extensive Disease Small-Cell Lung Cancer: Final Results of a Randomized Phase III Trial
T. Fink (2012)
Gender differences in genetic susceptibility for lung cancer.
C. Dresler (2000)
Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database.
B. Lally (2009)
A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database.
T. Hernandez-Boussard (1998)
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
S. Kudoh (2006)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
N. Hanna (2004)
The potential role of lung microbiota in lung cancer attributed to household coal burning exposures
H. Hosgood (2014)
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
P. Zatloukal (2010)
Epidemiology of lung cancer in women: risk factors, survival, and screening.
S. Kligerman (2011)
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
M. Reck (2009)
Bronchioloalveolar carcinoma: a review.
D. Raz (2006)
Gender differences in clinical registration trials: is there a real problem?
G. Labots (2018)
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
M. Socinski (2018)
Androgen receptor and androgen-dependent gene expression in lung
L. Mikkonen (2010)
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.
S. Burdett (2015)
Does sex influence the impact that smoking, treatment interruption and impaired pulmonary function have on outcomes in limited stage small cell lung cancer treatment?
G. Videtic (2005)
Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials
R. Lilenbaum (2009)
Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.
A. Rossi (2012)
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
R. Lord (2002)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
D. Bell (2005)
p53 and K-ras mutations in lung cancers from former and never-smoking women.
K. Vähäkangas (2001)
Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
R. Tsuchiya (2005)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. Hellmann (2018)
Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.
D. Spigel (2016)
Sex differences in lung cancer susceptibility: a review.
C. Kiyohara (2010)
Comparing treatment strategies for stage I small cell lung cancer: A National Cancer Database study.
P. Paximadis (2017)
Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database
J. Remon (2017)
Androgen Pathway Manipulation and Survival in Patients with Lung Cancer
C. Harlos (2015)
A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
S. Kaul (1996)
Suppressive effects of androgens on the immune system.
A. Trigunaite (2015)
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review
D. Gilligan (2007)
Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
G. Rossi (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
M. Reck (2016)
DNA adducts, mutations and cancer.
K. Hemminki (1993)
BRAF fusions in clinically advanced non-small cell lung cancer: An emerging target for anti-BRAF therapies.
V. P. Reddy (2017)
Global epidemiology of lung cancer
J. Tyczynski (2006)
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
R. Jotte (2018)
Women and lung cancer: what is new?
C. North (2013)
Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.
A. Aupérin (2006)
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis
C. Wallis (2019)
p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels.
E. Kure (1996)
Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants.
K. Osterlind (1986)
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
F. Barlési (2013)
Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
André Bacellar Costa Lima (2011)
Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
J. Jett (2013)
Prognostic factors for patients with small cell lung carcinoma
M. Paesmans (2000)
Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study.
Q. Wei (2000)
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
A. Shaw (2009)
Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer
S. Antonia (2017)
Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis
A. Lopez-Chavez (2012)
Interplay between the lung microbiome and lung cancer.
Q. Mao (2018)
Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database.
Jennifer B. Fu (2005)
A meta-analysis of thoracic radiotherapy for small-cell lung cancer.
J. Pignon (1992)
E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC--Outcomes based on chemotherapy subsets.
H. Wakelee (2016)
Higher Lung Cancer Incidence in Young Women Than Young Men in the United States
A. Jemal (2018)
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
J. Eckardt (2007)
Comprehensive molecular profiling of lung adenocarcinoma
E. Lander (2014)
miRNA and mRNA expression analysis reveals potential sex-biased miRNA expression
L. Guo (2017)
Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
J. Eckardt (2006)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
F. Shepherd (2000)
Diet and alcohol consumption and lung cancer risk in the New York State Cohort (United States)
E. Bandera (2004)
Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.
M. Spitz (2001)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
E. Garon (2014)
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.
C. Gridelli (2018)
The TP53 gene, tobacco exposure, and lung cancer
S. Toyooka (2003)
Epidemiology of tobacco use in the United States
G. Giovino (2002)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
M. O'Brien (2006)
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
L. Paz-Ares (2012)
Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer
O. Roengvoraphoj (2017)
Nuclear Estrogen Receptor β in Lung Cancer: Expression and Survival Differences by Sex
A. Schwartz (2005)
Clinical and Molecular Predictors of PD‐L1 Expression in Non–Small‐Cell Lung Cancer: Systematic Review and Meta‐analysis
F. Petrelli (2018)
The Murine Lung Microbiome Changes During Lung Inflammation and Intranasal Vancomycin Treatment
K. K. Barfod (2015)
Gender difference in the activity but not expression of estrogen receptors α and β in human lung adenocarcinoma cells
Susan M. Dougherty (2006)
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
A. Ardizzoni (2007)
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
J. Mazières (2013)
Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival.
M. Wolf (1991)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
S. Antonia (2016)
Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer
L. Paz-Ares (2018)
Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models
P. Beltran (2008)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
J. Schiller (2002)
Do women live longer following lung resection for carcinoma?
C. Alexiou (2002)
Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
G. des Guetz (2012)
Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer
C. Corso (2015)
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
D. Finkelstein (1986)
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
F. Conforti (2018)
Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer
Jurgita Jackutė (2018)
Characteristics and Outcomes of Patients With Metastatic KRAS‐Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
B. El Osta (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.
M. Cote (2009)
Prospective screening for ALK: clinical features and outcome according to ALK status.
V. Fallet (2014)
Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis.
P. Warde (1992)
Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors
J. Brahmer (2017)
Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology.
B. Özdemir (2018)
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
G. Strauss (2008)
Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: a follow up study.
J. Seidegård (1990)
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.
K. Albain (1990)
Estrogen receptor signaling pathways in human non-small cell lung cancer
D. Márquez-Garbán (2007)
The biology and management of non-small cell lung cancer
R. Herbst (2018)
Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594
H. Wakelee (2006)
Gender Differences in the Recurrence Timing of Patients Undergoing Resection for Non-Small Cell Lung Cancer
Katsuya Watanabe (2018)
Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent
J. Pujol (2000)
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
A. Rossi (2014)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
A. Sandler (2006)
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
J. Paik (2012)
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Z. Pan (2015)
Lung cancer in women.
Raúl Barrera-Rodríguez (2012)
Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry
N. Dobbs (2004)
US lung cancer trends by histologic type
M. Patel (2015)
Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ER&agr;-Positive Cancer Cell Lines
L. Yang (2017)
Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients
J. Vidal (2014)
Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
M. Zukin (2013)
The Role of the Estrogen Pathway in the Tumor Microenvironment
N. Rothenberger (2018)
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
L. Stabile (2005)
Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts
S. Mollerup (2006)
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.
S. Burdett (2008)
Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2
E. Rapley (2000)
Lung cancer in never smokers — a different disease
S. Sun (2007)
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.
H. Saito (2006)
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
L. Paz-Ares (2013)
Specific Features of Non-small Cell Lung Cancer in Women: A Retrospective Study of 1738 Cases Diagnosed in Bas-Rhin between 1982 and 1997
J. Foeglé (2007)
Adjuvant chemotherapy in non-small cell lung cancer: state-of- the-art
Á. A. Cortes (2015)
PD-L1 expression is associated with advanced non-small cell lung cancer
Z. Chen (2016)
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer.
J. Soria (2013)
Doublet Versus Single Cytotoxic Agent as First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
W. Qi (2012)
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.
P. Wheatley-Price (2010)
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
S. Burdett (2014)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis
C. Lee (2018)
OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
V. A. Papadimitrakopoulou (2018)
Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.
J. Brahmer (2017)
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non–Small Cell Lung Cancer
P. Martínez (2019)
Estrogen, Estrogen Receptor and Lung Cancer
L. Hsu (2017)
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
K. Albain (1991)
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
A. Ramos-Esquivel (2017)
Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: A population-based study.
S. Chu (2017)
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
K. Kubota (2014)
Female patients with small cell lung cancer live longer than male patients.
B. Johnson (1988)
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics
T. Cheng (2016)
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Yue-lun Zhang (2016)
Anti-PD1 treatment to induce M1 polarization of tumor infiltrating macrophages in a 3D ex vivo system of lung cancer patients.
Melanie Mediavilla-Varela (2017)
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis.
G. Bronte (2015)
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
J. O'connell (1986)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
C. Blakely (2017)
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
A. Traynor (2009)
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer
S. Lee (2008)
Lung cancer in women: role of estrogens
S. Chakraborty (2010)
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
J. Pignon (2008)
This paper is referenced by
Kidney Cancer Research: Sex Inclusive but Sex Unspecific
Darragh Waters (2020)
Enlarged Mediastinal Lymph Nodes in Computed Tomography are a Valuable Prognostic Factor in Non-Small Cell Lung Cancer Patients with Pathologically Negative Lymph Nodes
Yuansheng Zheng (2020)
Muscle derangement and alteration of the nutritional machinery in NSCLC.
I. Trestini (2019)
The radiotherapy cancer patient: female inclusive, but male dominated
A. Meunier (2020)
Cost-effectiveness of radon remediation programmes in the UK in the 2020s.
A. Denman (2020)